News

circle_logo2

CalciMedica Announces IDMC Recommendation to Continue with Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia

LA JOLLA, Calif., December 17, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (“CRAC”) channels for the …

CalciMedica Announces Publication of Preclinical Data Demonstrating the Pathological Role of Microglial CRAC Channels in Ischemic Stroke

First report of pathological role for microglial calcium activity in cortical spreading depolarization (CSD), a complication of stroke. CRAC channel inhibitors represent an important future …

CalciMedica Appoints Daniel Geffken as Interim Chief Financial Officer

Mr. Geffken brings more than three decades of financial experience to CalciMedica; involved in 12 IPO filings since 2013 LA JOLLA, Calif., November 5, 2020 …

CalciMedica Announces Peer-Reviewed Publication of Positive COVID-19 Data and Initiation of Blinded, Placebo-Controlled Trial of Auxora™ in Patients with Severe COVID-19 Pneumonia

Study published in Critical Care journal shows patients with severe COVID-19 pneumonia treated with Auxora and standard of care had substantially improved outcomes compared to …

CalciMedica and EpiPharma Enter into Research Collaboration to Discover and Develop CRAC Channel Inhibitor Therapies

Under the terms of the research collaboration agreement, CalciMedica will use EpiPharma’s state of the art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate …

Scroll to Top